Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin® litigation

Trials

Volumn 13, Issue , 2012, Pages

  Vedula, S S ^a   Goldman, Palko S ^b   Rona, Ilyas J ^b   Greene, Thomas M ^b   Dickersin, Kay ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b Greene LLP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN;

ARTICLE; BIPOLAR DISORDER; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HEALTH INSURANCE; HUMAN; MIGRAINE; NEUROPATHIC PAIN; NOCICEPTIVE PAIN; OFF LABEL DRUG USE; PUBLICATION;

ACCESS TO INFORMATION; AMINES; ANALGESICS; ANTIMANIC AGENTS; AUTHORSHIP; BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; CONFLICT OF INTEREST; CORRESPONDENCE AS TOPIC; CYCLOHEXANECARBOXYLIC ACIDS; DOCUMENTATION; DRUG COSTS; DRUG INDUSTRY; ELECTRONIC MAIL; EVIDENCE-BASED MEDICINE; FRAUD; GAMMA-AMINOBUTYRIC ACID; HUMANS; MARKETING OF HEALTH SERVICES; MIGRAINE DISORDERS; NEURALGIA; NOCICEPTIVE PAIN; OFF-LABEL USE; PERIODICALS AS TOPIC; PUBLICATION BIAS;

EID: 84864794912     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-13-136     Document Type: Article

References (60)

1. Ratner M, Gura T. Off-label or off-limits?. Nat Biotechnol 2008, 26:867-875. 10.1038/nbt0808-867, 18688236.
2. Mello MM, Studdert DM, Brennan TA. Shifting terrain in the regulation of off-label promotion of pharmaceuticals. N Engl J Med 2009, 360:1557-1566. 10.1056/NEJMhle0807695, 19357413.
3. Kesselheim AS, Mello MM, Studdert DM. Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. PLoS Med 2011, 8:e1000431. 10.1371/journal.pmed.1000431, 3071370, 21483716.
4. Food and Drug Administration Guidance for Industry - Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices 2012, Available from http://www.fda.gov/regulatoryinformation/guidances/ucm125126.htm, Food and Drug Administration.
5. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003, 326:1167-1170. 10.1136/bmj.326.7400.1167, 156458, 12775614.
6. Song F, Parekh S, Hooper L, Loke YK, Ryder J, Sutton AJ, Hing C, Kwok CS, Pang C, Harvey I. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess 2010, 14:1-193. iii, ix-xi.
7. Pande A. United States ex rel. Franklin v. Parke-Davis, 147 F. Supp.2d 39 (D. Mass. 2001), Exhibit 21. Interoffice memorandum from AtulPande to John Boris, re: " Gabapentin Approvals," and handwritten response 1995, X029227. , .
8. Steinman MA, Bero LA, Chren MM, Landefeld CS. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med 2006, 145:284-293.
9. In re Neurontin Marketing and Sales Practices Litigation, Civil Action No. 04-cv-10739-PBS, 2010 WL 4325225 2010, D. Mass, .
10. Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med 2009, 361:1963-1971. 10.1056/NEJMsa0906126, 19907043.
11. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA 1990, 263:1385-1389. 10.1001/jama.1990.03440100097014, 2406472.
12. Flanagin ACL, Fontanarosa PB, Phillips SG, Pace BP, Lundberg GD, Rennie D. Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA 1998, 280:222-224. 10.1001/jama.280.3.222, 9676661.
13. Boutron I, Dutton S, Ravaud P, Altman DG. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 2010, 303:2058-2064. 10.1001/jama.2010.651, 20501928.
14. Ulrich's Periodical Directory, Volume 3 2001, Bowker, New York, 39.
15. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, LaMoreaux L, Garofalo E. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998, 280:1831-1836. 10.1001/jama.280.21.1831, 9846777.
16. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003, 25:81-104. 10.1016/S0149-2918(03)90011-7, 12637113.
17. Caraceni A, Zecca E, Bonezzi C, Arcuri E, YayaTur R, Maltoni M, Visentin M, Gorni G, Martini C, Tirelli W, Barbieri M, De Conno F. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the gabapentin cancer pain study group. J Clin Oncol 2004, 22:2909-2917. 10.1200/JCO.2004.08.141, 15254060.
18. Dallocchio C, Buffa C, Mazzarello P, Chiroli S. Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain Symptom Manage 2000, 20:280-285. 10.1016/S0885-3924(00)00181-0, 11027910.
19. Gómez-Pérez FJ, Perez-Monteverde A, Nascimento O, Aschner P, Tagle M, Fichtner K, Subbiah P, Mutisya EM. Latin American Diabetic Neuropathy Study Group, Parsons B: Gabapentin for the treatment of painful diabetic neuropathy: dosing to achieve optimal clinical response. Br J Diab Vasc Dis Res 2004, 4:173-178.
20. Gordh TE, Stubhaug A, Jensen TS, Arner S, Biber B, Boivie J, Mannheimer C, Kalliomaki J, Kalso E. Gabapentin in traumatic nerve injury pain: a randomized, double-blind, placebo-controlled, cross-over, multi-center study. Pain 2008, 138:255-266. 10.1016/j.pain.2007.12.011, 18258368.
21. Gorson KC, Schott C, Herman R, Ropper AH, Rand WM. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry 1999, 66:251-252. 10.1136/jnnp.66.2.251, 1736215, 10071116.
22. Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, Stacey B, Tepper S. Efficacy of gabapentin in migraine prophylaxis. Headache 2001, 41:119-128.
23. Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000, 2:249-255. 10.1034/j.1399-5618.2000.20305.x, 11249802.
24. Serpell MG. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain 2002, 99:557-566. 10.1016/S0304-3959(02)00255-5, 12406532.
25. Vieta E, Manuel Goikolea J, Martinez-Aran A, Comes M, Verger K, Masramon X, Sanchez-Moreno J, Colom F. A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. J Clin Psychiatry 2006, 67:473-477. 10.4088/JCP.v67n0320, 16649836.
26. Wang PW, Santosa C, Schumacher M, Winsberg ME, Strong C, Ketter TA. Gabapentin augmentation therapy in bipolar depression. Bipolar Disord 2002, 4:296-301. 10.1034/j.1399-5618.2002.01211.x, 12479661.
27. Wessely P, Baumgartner C, Klingler D, et al. Preliminary results of a double-blind study with the new migraine prophylactic drug gabapentin. Cephalalgia 1987, 7:477-478.
28. In re Neurontin Marketing, Sales Practices, and Product Liability Litigation. Marketing Assessment. Neurontin® in migraine 1996, Bates No. Pfizer_JMarino_0001583 to Pfizer_JMarino_0001614, In re.
29. In re Neurontin Marketing, Sales Practices, and Product Liability Litigation. Medical Action Communications. Action Report 2001, Bates No. Pfizer_RGlanzman_0044634 to Pfizer_RGlanzman_0044637, In re.
30. In re Neurontin Marketing, Sales Practices, and Product Liability Litigation. Neurontin Publications Plan Meeting 2002, Bates No. Pfizer_LeslieTive_0091354 to Pfizer_LeslieTive_0091443, In re.
31. In re Neurontin Marketing, Sales Practices, and Product Liability Litigation. Email communication re: " spinning Serpell. 2002, MAC_0003664 to MAC_0003665, In re.
32. Serpell MG, . Neuropathic Pain Study Group Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial 2002, Presented at the Fifth International Conference on Mechanisms and Treatment of Neuropathic Pain Annual Meeting, Hamilton, Bermuda, poster, Neuropathic Pain Study Group.
33. Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001, 94:215-224. 10.1016/S0304-3959(01)00407-9, 11690735.
34. In re Neurontin Marketing, Sales Practices, and Product Liability Litigation. Email communication re: " Publication of Key Studies. 2001, Bates No. Pfizer_LCastro_0002679 to Pfizer_LCastro_0002680, In re.
35. In re Neurontin Marketing, Sales Practices, and Product Liability Litigation. Email communication re: " R[Redacted] contact information. 2002, Bates No. FAL007964 to FAL007965, In re.
36. Dickersin K. Reporting and other biases in studies of Neurontin for migraine, psychiatric/bipolar disorders, nociceptive pain, and neuropathic pain 2010, Available from http://dida.library.ucsf.edu/tid/oxx18r10.
37. In re Neurontin Marketing, Sales Practices, and Product Liability Litigation. Email communication re: " 25 and 26 studies. 2000, Bates No. Pfizer_LeslieTive _0020985 to Pfizer_LeslieTive_0020986, In re.
38. In re Neurontin Marketing, Sales Practices, and Product Liability Litigation. Email communication re: " Revised draft of publication for 945-224. 2000, Bates No. Pfizer_LeslieTive _0020922 to Pfizer_LeslieTive_0020923, In re.
39. In re Neurontin Marketing, Sales Practices, and Product Liability Litigation. Email communication re: " POPP Study. 2001, Bates No. Pfizer_JMarino_0000809, In re.
40. In re Neurontin Marketing, Sales Practices, and Product Liability Litigation. Email communication re: " POPP Study. 2001, Bates No. Pfizer_LeslieTive_0076418, In re.
41. In re Neurontin Marketing, Sales Practices, and Product Liability Litigation 2001, Pfizer Consultants Meeting, Crowne Plaza: Ann Arbor, Bates No. Pfizer_LKnapp_0050385 to Pfizer_LKnapp_0050389, In re.
42. In re Neurontin Marketing, Sales Practices, and Product Liability Litigation.Email communication re: " B[Redacted]. 2002, Bates No. Pfizer_RGlanzman_0157387 to Pfizer_RGlanzman_0157390, In re.
43. Sismondo S. Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry?. PLoS Med 2007, 4:e286. 10.1371/journal.pmed.0040286, 1989751, 17896859.
44. Sismondo S. Ghosts in the machine: publication planning in the medical sciences. Soc Stud Sci 2009, 39:171-198. 10.1177/0306312708101047, 19831220.
45. Chan AW, Krleza-Jeric K, Schmid I, Altman DG. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ 2004, 171:735-740. 10.1503/cmaj.1041086, 517858, 15451835.
46. Chan A-W, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004, 291:2457-2465. 10.1001/jama.291.20.2457, 15161896.
47. Rosenthal M. Estimate of units paid for by Neurontin endpayers that resulted from alleged fraudulent marketing by defendants, Declaration of Meredith Rosenthal 2012, Available from http://dida.library.ucsf.edu/tid/oxx18j10.
48. United States ex rel Franklin v. Parke-Davis, 147 F. Supp.2d 39 (D. Mass. 2001) Disclosure of Information by Relator David P. Franklin Pursuant to 31 USC § 3730 b, United States ex rel.
49. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?. JAMA 2003, 290:921-928. 10.1001/jama.290.7.921, 12928469.
50. Chan AW, Altman DG. Epidemiology and reporting of randomised trials published in PubMed journals. Lancet 2005, 365:1159-1162. 10.1016/S0140-6736(05)71879-1, 15794971.
51. Kjaergard LL, Als-Nielsen B. Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ. BMJ 2002, 325:249. 10.1136/bmj.325.7358.249, 117638, 12153921.
52. Saris P, . USDJ Findings of fact and conclusions of law, In re Neurontin Marketing and Sales Practices Litigation Civil Action No. 04-cv-10739-PBS, 2010 WL 4325225; 2010, USDJ.
53. Hill KP, Ross JS, Egilman DS, Krumholz HM. The ADVANTAGE seeding trial: a review of internal documents. Ann Intern Med 2008, 149:251-258.
54. Krumholz SD, Egilman DS, Ross JS. Study of Neurontin: Titrate to Effect, Profile of Safety (STEPS) Trial: a narrative account of a gabapentin seeding trial. Arch Intern Med 2011, 171:1100-1107. 10.1001/archinternmed.2011.241, 3319750, 21709111.
55. White J, Bero L. Corporate manipulation of research: strategies are similar across five industries. Stanford Law Policy Rev 2010, 21:105-133.
56. 42 C.F.R. § 76.110. 2012, Available from http://www.gpo.gov/fdsys.
57. 42 U.S.C. § 1320a-7(b)(15). 2012, Available from uscode.house.gov.
58. Fleder JR. The Park criminal liability doctrine: is it dead or is it awakening? Update 2009, September/October Available from http://www.hpm.com/pdf/FLEDERPARK.PDF Accessed on July 28, 2012.
59. Food and Drugs Administration: Regulatory Procedures Manual Regulatory Procedures Manual 2012, Available from http://www.fda.gov/ICECI/ComplianceManuals/RegulatoryProceduresManual/default.htm, Food and Drugs Administration: Regulatory Procedures Manual.
60. Tanne JH. Bayer to spend $20 m to correct misleading advertising for oral contraceptive Yaz. BMJ 2009, 338:b674. 10.1136/bmj.b674, 19223342.